Novo Nordisk's Semaglutide Franchise Widens in China and Paediatrics as Investors Await September Strategy Reset

China clears Wegovy for MASH, but Novo Nordisk shares remain weak after a Morgan Stanley downgrade and a heart failure study setback.

Novo Nordisk has secured a fresh regulatory green light in China, where Wegovy is now cleared for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), according to Reuters. The approval extends the reach of semaglutide — the Danish drugmaker's flagship molecule — into a new therapeutic territory at a moment when shareholders remain wary about the company's medium-term growth trajectory.

It lands alongside a run of clinical momentum. On Monday, Novo Nordisk reported that semaglutide hit its primary endpoint in the late-stage STEP Young trial involving children aged six to under twelve: after 68 weeks, 40.4% of participants on full treatment adherence were no longer classified as obese. The placebo arm recorded zero. No safety concerns relating to growth or pubertal development emerged, the company said. Semaglutide's relevance is thus broadening well beyond its original core patient groups.

A Cardiology Setback That Still Stings

Not everything in the pipeline has cooperated. The termination of two additional heart failure studies of ziltivekimab, disclosed the previous Wednesday, continues to weigh on sentiment. An independent monitoring committee concluded there was only a slim chance of a result diverging from the earlier failed cardiovascular trial. Since then the stock has shed roughly 3.4%. A separate post-heart-attack study is still running, with data not expected until the first half of 2027.

That mix — clinical wins in the core franchise, disappointments in pipeline diversification — is mirrored in how analysts are positioning. Morgan Stanley downgraded the shares from Neutral to Underweight on Friday, citing modest medium-term growth and the risk posed by semaglutide's expiring patent protection. Reuters reported the stock fell 2.4% that day. The bank estimates semaglutide accounted for 75% of group revenue in 2026, and projects it will still contribute 59% of sales by 2031, when patents lapse progressively in Europe and the US — a concentration risk Morgan Stanley deems excessive. A proprietary survey of 200 US primary care physicians also pointed to eroding market share against Eli Lilly's Zepbound and Mounjaro, as well as the rival product Retatrutide expected from 2027.

Not every house shares that caution. HSBC had already raised its price target to 320 Danish kroner on Wednesday. The gap between the two views underscores how contested Novo Nordisk's long-term growth outlook has become — and how pivotal the forthcoming capital markets day may prove in setting the stock's direction.

Price Action Reflects the Doubts

Friday's close came in at EUR 37.05, down 2.6% on the day and 7.6% over the week. Year-to-date the shares have lost 16%. Measured against the 52-week high of EUR 54.86 set on 23 January, the stock sits about 32% lower, while retaining a 22% cushion above its most recent annual low of EUR 30.25 touched on 2 March.

The technical picture reinforces the bearish tone. With an RSI of 34.1, the equity is approaching oversold territory, yet it continues to trade beneath both its 50-day average of EUR 41.20 and its 200-day average of EUR 40.09. Thirty-day volatility stands at 33% annualised — a signal that the market remains jittery about every new headline.

Adding another dimension to the competitive landscape, a company spokesperson confirmed earlier this month that Wegovy pills had launched in Germany. Investors are increasingly focused on oral competition from Eli Lilly, whose tablet-segment progress keeps Novo Nordisk's competitive position under scrutiny.

A Capital Markets Day Looms

Behind the share price turbulence, a strategic reset appears to be taking shape. On 15 September, the Danish insulin and diabetes group will convene an internal townhall with employees, according to a Bloomberg report, framed around the company's "next chapter." Six days later, on 21 September, the official capital markets day follows in London — the format at which management typically lays out its medium-term strategy to investors.

Meanwhile, Novo Nordisk continues to buy back its own stock. By 4 September, the company had repurchased roughly 32 million B-shares since February at an average price of 281.63 Danish kroner, equivalent to a transaction volume of just over 9 billion kroner. Up to 11.2 billion kroner is earmarked for repurchases through February 2027 — a signal that management considers its own equity undervalued despite the price decline.

For investors, the picture remains contradictory: solid clinical progress and ongoing capital returns stand against structural doubts about the long-term growth story. The China MASH approval hands the group a new growth avenue, yet it has done little so far to shift analysts' fundamental scepticism about medium-term earnings momentum. Whether management can convincingly address concerns about the post-semaglutide era may become clearer on 21 September.